Curated News
By: NewsRamp Editorial Staff
July 16, 2025
Lantern Pharma Partners with IBN to Boost Oncology Drug Development Communications
TLDR
- Lantern Pharma's partnership with IBN enhances investor awareness, offering a strategic advantage in the competitive biotech sector by showcasing its AI-driven oncology drug development pipeline.
- Lantern Pharma utilizes its RADR AI platform, analyzing over 200 billion data points, to streamline oncology drug development from AI insights to clinical trials in 2-3 years.
- Lantern Pharma's AI-driven approach to oncology drug development promises to improve cancer treatment outcomes, making significant strides towards a healthier tomorrow for patients worldwide.
- Discover how Lantern Pharma's RADR AI platform is revolutionizing cancer treatment by cutting drug development time and costs, a leap forward in precision oncology.
Impact - Why it Matters
This news highlights the intersection of artificial intelligence and oncology, showcasing how Lantern Pharma's innovative approach could significantly reduce the time and cost of cancer drug development. For patients, this means potentially faster access to life-saving treatments. For investors, it represents an opportunity to be part of a cutting-edge biotech firm that's making strides in precision medicine. The partnership with IBN further amplifies Lantern Pharma's visibility, ensuring that its advancements reach a broader audience, including potential investors and the medical community.
Summary
Lantern Pharma (NASDAQ: LTRN), a pioneering biotech firm, has partnered with InvestorBrandNetwork (IBN) to enhance its corporate communications strategy. Utilizing its innovative RADR(R) AI platform, Lantern Pharma is at the forefront of accelerating precision oncology drug development, with a focus on treating lung, brain, breast, and blood cancers. The company boasts a pipeline of three AI-guided drug candidates and a subsidiary dedicated to central nervous system (CNS) therapies, all undergoing active clinical trials. This collaboration with IBN is set to bolster investor awareness as Lantern Pharma approaches significant milestones in its data-driven, biomarker-informed drug development process. For more details, the full press release can be accessed here.
Lantern Pharma stands out in the biotech industry by leveraging over 200 billion oncology-focused data points and a suite of more than 200 machine learning algorithms through its RADR(R) platform. This approach has dramatically reduced the time and cost associated with bringing new cancer therapies to clinical trials, achieving milestones in just 2-3 years and at approximately $2.5 million per program. The company's efforts are supported by a team of world-class scientific advisors, underscoring its commitment to revolutionizing oncology drug development. Investors and stakeholders can stay updated on Lantern Pharma's progress through its newsroom at https://ibn.fm/LTRN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Partners with IBN to Boost Oncology Drug Development Communications
